OE 엔진룸 구성에 대한 큰 변화 없이 더욱 높은 온보드 전력 공급 대븐포트, 아이오와, 2025년 12월 1일 -- 오늘날 보안이나 방호, 혹은 까다로운 상업적 목적에 따라 차량을 개조할 때 닛산 패트롤(Nissan Patrol)은 신뢰할 수 있는 플랫폼으로 손색이 없는 자동차이다. 하지만 이러한 차량들은 일반적으로 장갑이나 특수 장비를 추가하여 업그레이드되다 보니 표준 OEM 알터네이터의 공급 용량을 넘어서는 전력이 필요할 때가 많다. 미국에 본사를 둔 아메리칸 파워 시스템스(American Power Systems, Inc. APS)에서 닛산 패트롤용 듀얼 알터네이터 브래킷 키트를 새롭게 출시한 이유도 바로 여기에 있다. 이 키트는 현장에서 신뢰할 수 있는 고출력 전력이 필요한 운전자들에게 매우 획기적인 솔루션이다. 새롭게 출시된 듀얼 알터네이터 브래킷 키트는 OE 엔진룸 구성을 크게 변경하지 않고도 5.6L V8 페트롤(가솔린) 엔진이 탑재된 2017-24 닛산 패트롤 Y62 차량에 전력을 추가로 공급한다. 특히 최종 사용자는 APS의 12V, 24V 또는 48V 고출력 알터네이터를 12-12, 12-24, 또
SANTA CLARA, Calif., Dec. 1, 2025 -- The Frost & Sullivan Institute is proud to announce the recipients of the 2025 Visionary Growth Leadership Best Practices Recognition, celebrating organizations that exemplify purpose-driven innovation, sustainable business models, and leadership committed to creating a positive global impact. This recognition highlights the companies that are spearheading meaningful change and addressing the global priorities identified by the Frost & Sullivan Institute. "The Visionary Growth Leadership Best Practices Recognition celebrates companies t
JOHOR BAHRU, Malaysia, Dec. 1, 2025 -- KPJ Healthcare Berhad ("KPJ Healthcare" or "the Group") today launched its first Centre of Excellence ("CoE") under the KPJ Health System ("KPJHS"), marking a decisive step in the Group's transformation into an integrated academic health system. The inaugural Heart & Lung CoE is established at Johor Specialist Hospital ("JSH") and will anchor a unified service line across KPJ's network through standardised clinical pathways, multidisciplinary reviews and data-driven improvement. Introd
SOLAIRIA-1 and SOLAIRIA-2 will evaluate GB-0895 in approximately 1,600 patients with severe asthma whose disease remains inadequately controlled on current therapies These are the first global Phase 3 studies of a long-acting anti-TSLP antibody, marking a pivotal step as GB-0895 advances the promise of programmable biology SOMERVILLE, Mass., Dec. 1, 2025 -- Generate:Biomedicines ("Generate") today announced it plans to initiate two global Phase 3 clinical trials, SOLAIRIA-1 and SOLAIRIA-2, evaluating GB-0895 in approximately 1,600 adults and adolescents with se
SOLAIRIA-1 및 SOLAIRIA-2 시험, 기존 요법으로 여전히 적절하게 조절되지 않는 중증 천식 환자 약 1600명 대상 GB-0895 평가 장기 지속형 항-TSLP 항체에 대한 최초의 글로벌 3상 시험...GB-0895, '프로그래머블 바이올로지'의 잠재력을 입증하며 중요한 진전 이뤄 서머빌, 매사추세츠, 2025년 12월 1일 -- 제너레이트 바이오메디슨(Generate:Biomedicines, 이하 '제너레이트')가 12월 1일 기존 요법에도 불구하고 여전히 적절하게 조절되지 않는 성인 및 청소년 중증 천식 환자 약 1600명을 대상으로 GB-0895를 평가하는 두 건의 글로벌 3상 임상시험(SOLAIRIA-1, SOLAIRIA-2)을 개시할 계획이라고 밝혔다. GB-0895는 AI로 설계된 장기 지속형 임상시험용 단일클론 항체로, 기도 염증을 유발하는 핵심 인자인 흉선 스트로마 림포포이에틴(TSLP)을 표적한다. 두 시험의 일차 목적은 52주 동안의 임상적으로 의미 있는 천식 악화 감소에 대한 GB-0895의 유효성을 평가하는 것이다. GB-0895는 AI를 활용해 초고친화도 TSLP 결합
HONG KONG, Dec. 1, 2025 -- Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or the "Group", stock code: 0950.HK) expresses its deep condolences to the victims of the serious fire at Wang Fuk Court in Tai Po, which caused multiple casualties and left many residents homeless and in urgent need of assistance. The Group has made a donation of HK$200,000 to the "Support Fund for Wang Fuk Court in Tai Po" established by the HKSAR Government to render assistance to residents of Wang Fuk Court and support all relevant works. As a pharmaceutical company listed
Driving faster delivery and broader portfolio access across the region. SINGAPORE, Dec. 1, 2025 -- CooperVision Asia Pacific, in collaboration with CEVA Logistics, has opened a new Regional Service Centre in Singapore, marking a significant milestone in both companies' commitment to enhance supply chain and logistics capabilities across the Asia Pacific region. Strategically located in CEVA's healthcare hub facility within Singapore's Airport Logistics Park, a designated free trade zone adjacent to Changi Airport, the centre marks the first phase of a broader in
Asia-led, "sovereign-by-design" platform built for secure, decentralised pathogen intelligence-sharing across borders aims to break data silos and provide faster "time to actionable insight" of outbreaks, from detection to control measures being in place. SINGAPORE, Dec. 1, 2025 -- Asia Pathogen Genomics Initiative (Asia PGI) today offered the first public preview of PathGen, an AI-powered sense-making and decision-making support platform of pathogen genomics and contextual data. Designed for public health practitioners, clinicians and industry, it can help detect e
COPENHAGEN, Denmark, Dec. 1, 2025 -- Danish diabetes‑tech company Hedia is implementing a leadership change effective 1 December 2025, when Rasmus Kofoed will take over as Chief Executive Officer (CEO). He succeeds Lars Christian Lund, who after approximately 2 years in the role has decided to step down to take up a Group CEO position in another international company. Hedia develops digital solutions that help people with insulin‑dependent diabetes to better understand and manage their treatment through data, artificial intelligence and user‑friendly app technology. Fou
Global sentiment analysis of 3,800 discussions from Reddit's r/Dentistry community highlights strong user recognition in software usability, workflow flexibility, and overall value. SEOUL, South Korea, Dec. 1, 2025 -- Medit, a leading digital dentistry company, has been ranked as the top intraoral scanner (IOS) brand in a global brand perception study conducted by an external insights agency. The study analyzed more than 3,800 publicly available discussions from the Reddit r/Dentistry community, where clinicians and users openly share their experiences with digital dentistry to